Clinic
Midstate Medical Center
Midstate Medical Center was paid $110.82M by Medicaid between Jan 2018 and Dec 2024, across 425 billing codes. Its largest line is 99285, emergency room visit (most serious) — 24% of everything it billed.
33Billing provider infoMIDSTATE MEDICAL CENTER
MERIDEN, CT 06451
MERIDEN, CT 06451
33aNPI1427007848assigned 05/10/2006
33bProvider typeEmergency Care Clinic/Center
28Total paid$110.82M
24GClaims2,176,560
24DCodes billed425
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Emergency Care Clinic/Center providers in Connecticut
Rank by total paid#3 of 6
Median peer was paid$80.66M
This provider vs. median1.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 313,284 | $15.16M | |
| 2019 | 302,413 | $15.36M | |
| 2020 | 274,768 | $12.57M | |
| 2021 | 326,509 | $16.62M | |
| 2022 | 331,750 | $17.23M | |
| 2023 | 321,150 | $17.06M | |
| 2024incomplete | 306,686 | $16.81M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 24% | 51,849 | 43,486 | $26.79M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 59,523 | 51,528 | $17.12M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.0% | 48,440 | 42,401 | $9.97M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 8.8% | 97,092 | 82,197 | $9.78M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.6% | 34,873 | 29,493 | $5.13M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.3% | 12,146 | 10,787 | $2.53M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.2% | 5,836 | 5,422 | $2.43M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 2.0% | 3,226 | 2,980 | $2.22M |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.6% | 31,753 | 25,350 | $1.77M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.6% | 12,529 | 5,048 | $1.76M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.2% | 3,166 | 2,907 | $1.34M |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 22,868 | 20,465 | $1.31M |
413 more codes
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 20,292 | $1.29M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 8,984 | $1.20M |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 25,360 | $1.17M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.0% | 10,632 | $1.12M |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 39,690 | $1.03M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 8,464 | $1.00M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 7,776 | $944K |
| 95811 | <1% | 2,158 | $907K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 21,468 | $905K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 11,200 | $903K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 13,129 | $764K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 5,127 | $718K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 6,694 | $706K |
| 47562 | <1% | 161 | $647K | |
| 71045 | Radiologic examination, chest; single view | <1% | 13,018 | $643K |
| 93975 | <1% | 3,125 | $640K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,201 | $602K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,987 | $595K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 5,545 | $591K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 4,561 | $582K |
| 11043 | <1% | 3,021 | $533K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,140 | $505K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,918 | $498K |
| 59025 | Fetal non-stress test | <1% | 2,804 | $446K |
| 27447 | <1% | 297 | $437K | |
| 76641 | <1% | 4,549 | $397K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 18,580 | $393K |
| 76830 | Ultrasound, transvaginal | <1% | 3,277 | $334K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 3,457 | $327K |
| 77065 | Tomosynthesis, mammo | <1% | 3,112 | $320K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,309 | $314K |
| 52356 | <1% | 93 | $282K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,935 | $278K |
| 77066 | Tomosynthesis, mammo | <1% | 2,321 | $264K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,040 | $254K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,043 | $252K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 6,277 | $233K |
| 76642 | <1% | 3,495 | $212K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,587 | $202K |
| 93971 | <1% | 2,903 | $193K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,219 | $192K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 419 | $186K |
| 76801 | <1% | 1,774 | $178K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 964 | $175K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 4,162 | $169K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,369 | $168K |
| 76770 | <1% | 1,991 | $162K | |
| 10060 | <1% | 951 | $152K | |
| 58558 | <1% | 83 | $149K | |
| 27130 | <1% | 78 | $146K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 340 | $134K |
| 74183 | <1% | 653 | $130K | |
| 72110 | <1% | 3,516 | $115K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,455 | $102K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 7,264 | $99K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 6,400 | $91K |
| 73564 | <1% | 4,776 | $86K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 2,474 | $85K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 139 | $85K |
| 72141 | <1% | 482 | $77K | |
| 97597 | <1% | 1,115 | $76K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 276 | $74K |
| 86900 | <1% | 5,834 | $71K | |
| 0001A | <1% | 2,287 | $71K | |
| 70496 | <1% | 520 | $69K | |
| 0002A | <1% | 2,140 | $69K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 3,599 | $64K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 718 | $63K |
| 71250 | <1% | 1,347 | $63K | |
| 97161 | <1% | 2,697 | $58K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,450 | $56K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 44,688 | $53K |
| 73221 | <1% | 277 | $50K | |
| 93970 | <1% | 361 | $49K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 10,611 | $43K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 1,611 | $43K |
| 96367 | <1% | 1,076 | $40K | |
| 72050 | <1% | 620 | $39K | |
| 74018 | <1% | 2,722 | $34K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,126 | $34K |
| 76536 | <1% | 424 | $33K | |
| 19083 | <1% | 27 | $31K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,703 | $30K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 11,534 | $30K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,704 | $30K |
| 73030 | <1% | 3,750 | $30K | |
| 99223 | Prolong inpt eval add15 m | <1% | 547 | $28K |
| 74220 | <1% | 283 | $27K | |
| 62323 | <1% | 80 | $26K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 215 | $25K |
| 73630 | <1% | 4,357 | $25K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 92,768 | $25K |
| 20553 | <1% | 344 | $24K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 246 | $24K |
| 36561 | <1% | 12 | $24K | |
| 10061 | <1% | 67 | $23K | |
| 80053 | Comprehensive metabolic panel | <1% | 75,647 | $23K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 711 | $22K |
| 96415 | <1% | 499 | $21K | |
| 93798 | <1% | 389 | $21K | |
| 97116 | <1% | 1,501 | $21K | |
| 73502 | <1% | 2,427 | $20K | |
| 73130 | <1% | 3,392 | $19K | |
| 43235 | <1% | 52 | $19K | |
| 70486 | <1% | 1,116 | $19K | |
| 97162 | <1% | 796 | $19K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 169 | $19K |
| 73110 | <1% | 2,632 | $19K | |
| 74019 | <1% | 954 | $18K | |
| 72131 | <1% | 518 | $17K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 46 | $17K |
| 96417 | <1% | 508 | $17K | |
| 77336 | <1% | 330 | $17K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 253 | $16K |
| 73610 | <1% | 4,198 | $16K | |
| 77334 | <1% | 73 | $13K | |
| 93017 | <1% | 247 | $13K | |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion | <1% | 110 | $12K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 1,135 | $12K |
| 76813 | <1% | 134 | $12K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 269 | $11K |
| 72040 | <1% | 538 | $11K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 120 | $11K |
| 99254 | <1% | 119 | $11K | |
| 88342 | <1% | 2,583 | $11K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 427 | $11K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 3,950 | $10K |
| 76857 | <1% | 108 | $10K | |
| 70491 | <1% | 59 | $9K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 406 | $9K |
| 0031A | <1% | 423 | $9K | |
| 97165 | <1% | 227 | $8K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 13 | $8K |
| 82728 | <1% | 1,310 | $8K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 13 | $8K |
| 72197 | <1% | 13 | $7K | |
| 73140 | <1% | 2,023 | $7K | |
| 78264 | <1% | 24 | $7K | |
| 72158 | <1% | 28 | $7K | |
| 72100 | <1% | 228 | $7K | |
| 76970 | <1% | 64 | $6K | |
| G0378 | Hospital observation service, per hour | <1% | 10,792 | $6K |
| 73080 | <1% | 1,282 | $6K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 21 | $6K |
| 91040 | <1% | 28 | $6K | |
| 76870 | <1% | 183 | $6K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 22,278 | $6K |
| 72070 | <1% | 164 | $6K | |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 29 | $5K |
| 0011A | <1% | 185 | $5K | |
| J1442 | Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | <1% | 74 | $5K |
| 29515 | <1% | 49 | $5K | |
| 83550 | <1% | 1,249 | $5K | |
| 73560 | <1% | 649 | $5K | |
| 78226 | <1% | 27 | $5K | |
| 0012A | <1% | 172 | $5K | |
| 96411 | <1% | 150 | $5K | |
| 12001 | <1% | 1,708 | $4K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 470 | $4K |
| 95806 | <1% | 53 | $4K | |
| 73700 | <1% | 111 | $4K | |
| 83540 | <1% | 1,259 | $4K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 11,013 | $4K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 34,402 | $4K |
| 92610 | <1% | 58 | $4K | |
| 43450 | <1% | 14 | $3K | |
| 99253 | <1% | 68 | $3K | |
| 74240 | <1% | 28 | $3K | |
| 0064A | <1% | 77 | $3K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 10,055 | $3K |
| 72081 | <1% | 29 | $3K | |
| 93308 | <1% | 13 | $2K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 115 | $2K |
| 70498 | <1% | 483 | $2K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 16,019 | $2K |
| 0004A | <1% | 57 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 8,909 | $2K |
| 95816 | <1% | 13 | $2K | |
| 73590 | <1% | 625 | $2K | |
| J1447 | Injection, tbo-filgrastim, 1 microgram | <1% | 40 | $2K |
| 88184 | <1% | 14 | $2K | |
| 99241 | <1% | 60 | $2K | |
| 93880 | <1% | 14 | $2K | |
| 74181 | <1% | 13 | $2K | |
| 74174 | <1% | 15 | $2K | |
| 83735 | <1% | 21,457 | $2K | |
| 82378 | <1% | 326 | $2K | |
| 71100 | <1% | 380 | $2K | |
| 76882 | <1% | 24 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,558 | $1K |
| 85610 | <1% | 14,567 | $1K | |
| 80061 | Lipid panel | <1% | 231 | $1K |
| 83615 | <1% | 1,377 | $1K | |
| 82784 | <1% | 206 | $1K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,368 | $1K |
| 93976 | <1% | 16 | $1K | |
| 85379 | <1% | 4,193 | $1K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 11,613 | $1K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,467 | $983.80 |
| 81025 | <1% | 26,717 | $948.32 | |
| 82607 | <1% | 162 | $863.40 | |
| 85730 | <1% | 2,272 | $824.12 | |
| 73090 | <1% | 274 | $813.90 | |
| 84703 | <1% | 2,705 | $793.12 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 366 | $777.27 |
| 71101 | <1% | 112 | $736.48 | |
| 83883 | <1% | 90 | $723.88 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 1,789 | $649.02 |
| 0054A | <1% | 16 | $600.00 | |
| 73660 | <1% | 52 | $586.11 | |
| 90686 | <1% | 62 | $570.90 | |
| 86780 | <1% | 56 | $568.80 | |
| 99242 | <1% | 23 | $516.24 | |
| 84484 | <1% | 31,180 | $494.83 | |
| 0003A | <1% | 14 | $480.00 | |
| 36591 | <1% | 16 | $479.72 | |
| 87641 | <1% | 282 | $468.01 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 13,696 | $463.27 |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 396 | $457.13 |
| 85045 | <1% | 274 | $445.89 | |
| 83690 | <1% | 26,528 | $442.38 | |
| 83880 | <1% | 5,469 | $440.33 | |
| 87077 | <1% | 7,967 | $379.04 | |
| 85652 | <1% | 1,646 | $374.55 | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 36 | $358.60 |
| 72170 | <1% | 128 | $350.88 | |
| 88360 | <1% | 64 | $348.60 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,695 | $322.53 |
| 86850 | <1% | 5,120 | $306.72 | |
| 90715 | <1% | 3,448 | $291.11 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,436 | $277.22 |
| 82962 | <1% | 29,993 | $247.73 | |
| 87186 | <1% | 5,037 | $246.30 | |
| 81001 | <1% | 10,587 | $235.40 | |
| 86901 | <1% | 5,842 | $224.37 | |
| 81003 | <1% | 30,271 | $218.37 | |
| 83605 | <1% | 7,985 | $196.31 | |
| 29125 | <1% | 272 | $192.22 | |
| 84702 | <1% | 3,447 | $181.63 | |
| 86140 | <1% | 605 | $161.71 | |
| 96376 | <1% | 6,569 | $157.22 | |
| 73060 | <1% | 15 | $138.30 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 18,577 | $131.59 |
| 82803 | <1% | 1,230 | $121.10 | |
| 87070 | <1% | 5,814 | $118.25 | |
| J3490 | Unclassified drugs | <1% | 288,458 | $118.06 |
| 88304 | <1% | 1,904 | $115.47 | |
| 99449 | <1% | 12 | $109.20 | |
| 93356 | <1% | 192 | $106.10 | |
| 80076 | <1% | 2,679 | $102.06 | |
| 87040 | <1% | 7,994 | $101.79 | |
| 82746 | <1% | 14 | $98.28 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 47,155 | $93.72 |
| 84165 | <1% | 18 | $92.34 | |
| 87400 | <1% | 2,898 | $91.60 | |
| 82550 | <1% | 6,581 | $90.93 | |
| 85027 | <1% | 3,048 | $84.66 | |
| 87081 | <1% | 2,964 | $67.63 | |
| 69209 | <1% | 147 | $60.54 | |
| 82077 | <1% | 767 | $56.18 | |
| 81002 | <1% | 4,239 | $48.97 | |
| 86618 | <1% | 580 | $48.81 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 863 | $43.26 |
| 84155 | <1% | 18 | $34.35 | |
| 87640 | <1% | 12 | $33.51 | |
| 80143 | <1% | 280 | $33.00 | |
| 80179 | <1% | 265 | $33.00 | |
| 87205 | <1% | 4,559 | $28.51 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 14 | $28.28 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,141 | $28.20 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 5,069 | $25.39 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,737 | $24.57 |
| 82010 | <1% | 1,300 | $22.16 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 22,832 | $22.14 |
| 76376 | <1% | 218 | $16.97 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 444 | $16.30 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,873 | $15.58 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 6,607 | $14.48 |
| 84100 | <1% | 939 | $13.56 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 29,467 | $13.55 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 2,576 | $12.71 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 312 | $12.03 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 6,290 | $10.98 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 45 | $10.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 8,371 | $8.98 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 11,535 | $6.91 |
| G0008 | Administration of influenza virus vaccine | <1% | 64 | $6.00 |
| 87184 | <1% | 443 | $5.88 | |
| 82570 | <1% | 91 | $4.94 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,516 | $4.60 |
| 84156 | <1% | 87 | $3.50 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 21,274 | $3.05 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,543 | $2.02 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,945 | $2.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 25,775 | $1.95 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 121 | $1.09 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 5,530 | $1.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 467 | $0.80 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 468 | $0.79 |
| 84550 | <1% | 250 | $0.46 | |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | <1% | 73 | $0.09 |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 73 | $0.09 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 8,770 | $0.08 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 4,582 | $0.02 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 430 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 2,294 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 82 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 307 | $0.00 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 0% | 284 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 2,072 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 6,568 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 2,007 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 74 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 1,081 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 298 | $0.00 |
| 99152 | 0% | 632 | $0.00 | |
| 12011 | 0% | 532 | $0.00 | |
| 91300 | 0% | 4,390 | $0.00 | |
| J9190 | Injection, fluorouracil, 500 mg | 0% | 225 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 242 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 414 | $0.00 |
| 84439 | 0% | 50 | $0.00 | |
| 87207 | 0% | 93 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 113 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 16 | $0.00 |
| 76937 | 0% | 76 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 68 | $0.00 |
| J0670 | Injection, mepivacaine hydrochloride, per 10 ml | 0% | 334 | $0.00 |
| 82565 | 0% | 29 | $0.00 | |
| C1758 | Catheter, ureteral | 0% | 43 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 150 | $0.00 |
| 87075 | 0% | 30 | $0.00 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 114 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 236 | $0.00 |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | 0% | 81 | $0.00 |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 0% | 24 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 117 | $0.00 |
| J0640 | Injection, leucovorin calcium, per 50 mg | 0% | 119 | $0.00 |
| 90840 | 0% | 47 | $0.00 | |
| 80164 | 0% | 32 | $0.00 | |
| 64447 | 0% | 21 | $0.00 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 0% | 100 | $0.00 |
| J3260 | Injection, tobramycin sulfate, up to 80 mg | 0% | 30 | $0.00 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | 0% | 47 | $0.00 |
| 82140 | 0% | 14 | $0.00 | |
| 88112 | 0% | 45 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 14 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 38 | $0.00 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 12 | $0.00 |
| 87469 | 0% | 13 | $0.00 | |
| 88312 | 0% | 13 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 12,259 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 3,515 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 3,270 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 11,053 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 480 | $0.00 |
| 11045 | 0% | 2,063 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 2,418 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 1,303 | $0.00 |
| C1769 | Guide wire | 0% | 1,879 | $0.00 |
| A4301 | Implantable access total catheter, port/reservoir (e.g., venous, arterial, epidural, subarachnoid, peritoneal, etc.) | 0% | 3,078 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 32,684 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 751 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 4,450 | $0.00 |
| 12002 | 0% | 256 | $0.00 | |
| A4217 | Sterile water/saline, 500 ml | 0% | 112 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 6,535 | $0.00 |
| 90839 | 0% | 214 | $0.00 | |
| 88341 | 0% | 527 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 15 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 1,577 | $0.00 |
| A4648 | Tissue marker, implantable, any type, each | 0% | 551 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 10,180 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 956 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 943 | $0.00 |
| 88307 | 0% | 127 | $0.00 | |
| 86308 | 0% | 81 | $0.00 | |
| 87015 | 0% | 236 | $0.00 | |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 338 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 3,687 | $0.00 |
| 77001 | 0% | 28 | $0.00 | |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 5,147 | $0.00 |
| A6213 | Foam dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., with any size adhesive border, each dressing | 0% | 116 | $0.00 |
| 87808 | 0% | 153 | $0.00 | |
| 99153 | Mod sedat endo service >5yrs | 0% | 265 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 556 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 235 | $0.00 |
| 91301 | 0% | 404 | $0.00 | |
| 36416 | 0% | 77 | $0.00 | |
| 88300 | 0% | 514 | $0.00 | |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 213 | $0.00 |
| 87486 | 0% | 100 | $0.00 | |
| 95885 | 0% | 68 | $0.00 | |
| 74420 | 0% | 30 | $0.00 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 196 | $0.00 |
| 96368 | 0% | 208 | $0.00 | |
| 87484 | 0% | 65 | $0.00 | |
| 82553 | 0% | 200 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 52 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 204 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 35 | $0.00 |
| 64488 | 0% | 46 | $0.00 | |
| 87468 | 0% | 65 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 173 | $0.00 |
| 87581 | 0% | 100 | $0.00 | |
| 91303 | 0% | 230 | $0.00 | |
| 87807 | 0% | 86 | $0.00 | |
| 83930 | 0% | 126 | $0.00 | |
| 91306 | 0% | 77 | $0.00 | |
| 88185 | 0% | 14 | $0.00 | |
| 86617 | 0% | 17 | $0.00 | |
| 91305 | 0% | 16 | $0.00 | |
| 11046 | 0% | 23 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBOISVERT, GERALD (VP CFO)
| Provider | Location | Paid |
|---|---|---|
| Hartford Hospital | Hartford, CT | $16K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.